Sort   by:  
 Page size 
TranscriptomicsIGR_CAP1_DOCETAXEL_GE_STUDY_NN
Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance by mechanisms that remain largely unknown. It is thus important to define the relevant pathways implicated in docetaxel-resistance and v...
ORGANISM(S): Homo sapiens 
2013-06-30 | E-MTAB-1221 | biostudies-arrayexpress
TranscriptomicsDistinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
Background: Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult ...
ORGANISM(S): Homo sapiens 
2013-07-22 | E-GEOD-39337 | biostudies-arrayexpress
TranscriptomicsExpression data from docetaxel-resistant prostate cancer cell lines
Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 ...
ORGANISM(S): Homo sapiens 
2012-01-01 | E-GEOD-33455 | biostudies-arrayexpress
TranscriptomicsAcquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways”
Two breast cancer cell lines, MCF-7 and MDA-MB-213, were treated progressively with docetaxel.
ORGANISM(S): Homo sapiens 
2014-09-01 | E-MEXP-3982 | biostudies-arrayexpress
TranscriptomicsExpression data from Docetaxel-resistant prostate cancer cells
Docetaxel is the standard first line therapy for hormone-refractory prostate cancer patients. Here we generated models of Docetaxel resistance in prostate cancer cells to study the molecular pathways that drive the acquisition of resistance to this therapy. We used microarrays to detail the global p...
ORGANISM(S): Homo sapiens 
2012-10-02 | E-GEOD-36135 | biostudies-arrayexpress
GenomicsSingle Cell Analysis Reveals NUPR1 Promotes Docetaxel Resistance in Prostate Cancer
Single Cell Analysis Reveals NUPR1 Promotes Docetaxel Resistance in Prostate Cancer
PRJNA589746 | ENA
GenomicsTranscription Factor Network Reveals New Treatments for Prostate Cancer Docetaxel Drug Resistance
Transcription Factor Network Reveals New Treatments for Prostate Cancer Docetaxel Drug Resistance
PRJNA629596 | ENA
GenomicsPatient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer
Patient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer
PRJNA1425300 | ENA
TranscriptomicsSingle Cell Analysis Reveals NUPR1 Promotes Docetaxel Resistance in Prostate Cancer
The majority of prostate cancer (PCa) patients treated with docetaxel develop resistance to it. In order to better understand the mechanism behind the acquisition of resistance, we conducted single cell total RNA sequencing (sctotal RNA-seq) of docetaxel sensitive and resistant variants of DU145 and...
ORGANISM(S): Homo sapiens 
2020-09-01 | GSE140440 | GEO
TranscriptomicsTranscription Factor Network Reveals New Treatments for Prostate Cancer Docetaxel Drug Resistance
Overcoming drug resistance is critical increasing the survival rate for prostate cancer (PCa). In this study, we modeled­ docetaxel resistance using two PCa cell lines, DU145 and PC3. We conducted both single cell and bulk RNA sequencing. We constructed a transcription factor (TF) network for the do...
ORGANISM(S): Homo sapiens 
2023-04-01 | GSE149681 | GEO
Sort   by:  
 Page size